Fig. 3

MEIS1 enhances oxaliplatin sensitivity to regress CRC cells by preventing DNA repair to trigger apoptosis. a, b si-MEIS1, oe-MEIS1, and corresponding control cells were treated with increasing concentrations of oxaliplatin for 48 h. Cell viability was determined by the CCK-8 assay (left), and the IC50 values were calculated based on nonlinear regression analysis (right). c–f Flow cytometry assays (c, d) and western blotting (e, f) were used to examine the effect of MEIS1 on the apoptosis of cells treated with oxaliplatin (5 μM) for 48 h. g, h Western blot was used to examine the γ-H2A.X levels in CRC cells treated with oxaliplatin (5 μM) for 24 h. i, j IF was used to examine γ-H2A.X foci in CRC cells treated with oxaliplatin (5 μM) for 24 h. k MEIS1 mRNA levels in samples from the GSE69657 dataset. Response, response to oxaliplatin; noResponse, no response to oxaliplatin. l ROC curves for predicting oxaliplatin resistance in the GSE69657 dataset. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001